Accuracy and validation of a point-of-care blood glucose monitoring system for use in horses.
Authors: Velineni Sridhar, Schiltz Paul, Chang Ko-Hsin, Peng Yi-Ming, Cowles Bobby
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Abnormal blood glucose in critically ill horses significantly predicts poor outcomes, yet rapid bedside assessment has traditionally required expensive laboratory analysis. Sridhar and colleagues validated the AlphaTrak 3 glucometer—the first point-of-care device with an equine-specific algorithm—against the Beckman Coulter AU480 reference analyser using ISO15197:2013 standards across a glucose range of 29–479 mg/dL. Both laboratory verification (98.9% of 129 samples) and field validation (98.4% of 96 horses) demonstrated accuracy within ±15 mg/dL or ±15%, with 99–100% of readings falling into consensus error grid zone A, indicating negligible risk of clinically harmful misinterpretation. For practitioners managing critically ill or metabolically compromised horses, the AT3 offers genuine clinical utility: stall-side glucose monitoring at minimal cost enables frequent serial measurements and rapid treatment decisions without sending samples to distant laboratories. This represents a meaningful advance in evidence-based equine practice, particularly valuable for field practitioners, competition settings, and clinical environments where swift metabolic assessment can influence outcome.
Read the full abstract on PubMed
Practical Takeaways
- •The AlphaTrak 3 is now a validated, dependable tool for rapid blood glucose monitoring in your barn or clinic—use it confidently for real-time clinical decisions in sick horses without waiting for lab results
- •At 98%+ accuracy across a wide glucose range, this device is accurate enough to guide treatment decisions and monitor response to therapy in critical cases
- •Cost-effective frequent monitoring is now practical: you can check glucose levels multiple times daily to track trends and adjust management without laboratory delays or expense
Key Findings
- •AlphaTrak 3 device with equine-specific algorithm achieved 98.9% accuracy in artificially adjusted samples (range 29-479 mg/dL) within ISO15197:2013 threshold of ±15 mg/dL or ±15%
- •100% of AT3 measurements fell in consensus error grid zone A in controlled testing, indicating minimal risk of adverse clinical impact
- •Field validation in 96 horses showed 98.4% accuracy and 99.2% zone A placement, confirming clinical reliability
- •Point-of-care device enables stall-side monitoring at minimal cost compared to reference laboratory methods